Chaudhury Sayantanee, Panda Swagatika, Mohanty Neeta, Panda Saurav, Mohapatra Diksha, Nagaraja Ravishankar, Sahoo Alkananda, Gopinath Divya, Lewkowicz Natalia, Lapinska Barbara
Department of Oral Pathology and Microbiology, Institute of Dental Sciences, Siksha 'O' Anusandhan, Deemed to be University, Bhubaneswar 751003, India.
Department of Periodontics and Implantology, Institute of Dental Sciences, Siksha 'O' Anusandhan, Deemed to be University, Bhubaneswar 751003, India.
J Clin Med. 2023 Apr 7;12(8):2753. doi: 10.3390/jcm12082753.
The objective was to evaluate the association of the immunoexpression of cancer stem cell (CSC) markers with clinicopathological and survival outcomes in tongue squamous cell carcinoma (TSCC) patients. This systematic review and meta-analysis [PROSPERO (CRD42021226791)] included observational studies that compared the association of clinicopathological and survival outcomes with CSC immunoexpression in TSCC patients. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were used as outcome measures. Six studies identified the association with three surface markers (c-MET, STAT3, CD44) and four transcription markers (NANOG, OCT4, BMI, SOX2). The odds of early-stage presentation were 41% (OR = 0.59, 95% CI 0.42-0.83) and 75% (OR = 0.25; 95% CI 0.14-0.45) lower in CSC and SOX2 immuno-positive cases than immuno-negative cases, respectively. The odds of well-differentiated tumors in transcription marker immuno-positive cases were 45% lower compared to immuno-negative cases (OR = 0.55, 95% CI 0.32-0.96). The odds of positive lymph nodes were 2.01 times higher in CSC immuno-positive cases compared to immuno-negative cases (OR = 2.01, 95% CI 1.11-3.65). Mortality in immuno-positive cases was 121% higher than that in immuno-negative cases (HR = 2.21; 95% CI 1.16-4.21). Advanced tumor staging and grading, lymph node metastasis, and mortality were significantly associated with positive immunoexpression of CSC markers.
目的是评估癌症干细胞（CSC）标志物的免疫表达与舌鳞状细胞癌（TSCC）患者临床病理及生存结果之间的关联。本系统评价和荟萃分析[国际前瞻性系统评价注册库（PROSPERO，注册号CRD42021226791）]纳入了比较TSCC患者临床病理及生存结果与CSC免疫表达之间关联的观察性研究。采用合并比值比（OR）和风险比（HR）及95%置信区间（CI）作为结局指标。六项研究确定了与三种表面标志物（c-MET、STAT3、CD44）和四种转录标志物（NANOG、OCT4、BMI、SOX2）的关联。与免疫阴性病例相比，CSC和SOX2免疫阳性病例早期表现的几率分别降低41%（OR = 0.59，95% CI 0.42 - 0.83）和75%（OR = 0.25；95% CI 0.14 - 0.45）。与免疫阴性病例相比，转录标志物免疫阳性病例中高分化肿瘤的几率降低45%（OR = 0.55，95% CI 0.32 - 0.96）。与免疫阴性病例相比CSC免疫阳性病例中阳性淋巴结的几率高2.01倍（OR = 2.01，95% CI 1.11 - 3.65）免疫阳性病例的死亡率比免疫阴性病例高121%（HR = 2.21；95% CI 1.16 - 4.21）。肿瘤的晚期分期和分级、淋巴结转移及死亡率与CSC标志物的阳性免疫表达显著相关。
